Fig. 3

Analytical performance of αSyn RT-QuIC assay for a large collection of CSF samples from neuropathologically confirmed cases of PD, DLB, and NS controls. a RT-QuIC spectra of postmortem CSF samples from 40 cases of neuropathologically confirmed PD patients and 40 NS controls. b RT-QuIC spectra of postmortem CSF from 30 cases of DLB patients and 30 NS controls. c Scattered plot of RT-QuIC reactivity as percentages of maximum ThT fluorescence at the end of 60 h assay of 214 neuropathologically confirmed CSF cases, including those with PD (n = 88) and DLB (n = 58), as well as NS control cases (n = 68) including those neurologically normal (n = 23), and those with amyotrophic lateral sclerosis (ALS, n = 9), multiple sclerosis (MS, n = 6), Alzheimer’s disease (AD, n = 7), Pick’s disease (n = 10), corticobasal degeneration (CBD, n = 4), and progressive supranuclear palsy (PSP, n = 9). Horizontal bars were means ± S.E. of ThT fluorescence for each group of CSF cases. The dotted line represents the threshold (11%) defining the positive and negative cases. All RT-QuIC reactions were seeded with 200 nl of CSF (2 µl of tenfold-diluted CSF) in quadruplicate wells per sample. *p < 0.05 comparing PD with DLB, **** p < 0.0001 comparing the combined PD and DLB group with all of the NS controls